Plasma prothrombin and coagulation factor VII procoagulant activity during oral anticoagulant treatment and vitamin K supplementation
| Vitamin K supplement . | INR . | FIIc, % . | FVIIc, % . | |||
|---|---|---|---|---|---|---|
| Mean . | SD . | Mean . | SD . | Mean . | SD . | |
| None, baseline | 0.99 | 0.04 | 112 | 6.7 | 129 | 12.6 |
| K1, μg/d | ||||||
| 0 | 2.02 | 0.34 | 46.3 | 9.0 | 52.7 | 23.5 |
| 50 | 1.89 | 0.26 | 45.7 | 7.1 | 49.4 | 16.6 |
| 100 | 1.79 | 0.31 | 50.0 | 8.4 | 50.3 | 23.6 |
| 150 | 1.74 | 0.26 | 48.3 | 14.2 | 44.3 | 17.2 |
| 200 | 1.60 | 0.20 | 55.0 | 8.0 | 56.4 | 23.5 |
| 250 | 1.53 | 0.18 | 59.3 | 7.5 | 62.9 | 19.4 |
| 300 | 1.47 | 0.24 | 61.9 | 6.7 | 71.8 | 29.1 |
| 500 | 1.35 | 0.17 | 64.5 | 9.5 | 75.4 | 30.1 |
| MK-7, μg/d | ||||||
| 0 | 1.98 | 0.42 | 45.7 | 12.5 | 48.5 | 28.8 |
| 95 | 1.66 | 0.29 | 53.7 | 13.6 | 64.4 | 25.2 |
| 190 | 1.37 | 0.24 | 63.8 | 10.5 | 72.9 | 27.9 |
| 285 | 1.24 | 0.13 | 70.8 | 11.3 | 78.4 | 20.3 |
| Vitamin K supplement . | INR . | FIIc, % . | FVIIc, % . | |||
|---|---|---|---|---|---|---|
| Mean . | SD . | Mean . | SD . | Mean . | SD . | |
| None, baseline | 0.99 | 0.04 | 112 | 6.7 | 129 | 12.6 |
| K1, μg/d | ||||||
| 0 | 2.02 | 0.34 | 46.3 | 9.0 | 52.7 | 23.5 |
| 50 | 1.89 | 0.26 | 45.7 | 7.1 | 49.4 | 16.6 |
| 100 | 1.79 | 0.31 | 50.0 | 8.4 | 50.3 | 23.6 |
| 150 | 1.74 | 0.26 | 48.3 | 14.2 | 44.3 | 17.2 |
| 200 | 1.60 | 0.20 | 55.0 | 8.0 | 56.4 | 23.5 |
| 250 | 1.53 | 0.18 | 59.3 | 7.5 | 62.9 | 19.4 |
| 300 | 1.47 | 0.24 | 61.9 | 6.7 | 71.8 | 29.1 |
| 500 | 1.35 | 0.17 | 64.5 | 9.5 | 75.4 | 30.1 |
| MK-7, μg/d | ||||||
| 0 | 1.98 | 0.42 | 45.7 | 12.5 | 48.5 | 28.8 |
| 95 | 1.66 | 0.29 | 53.7 | 13.6 | 64.4 | 25.2 |
| 190 | 1.37 | 0.24 | 63.8 | 10.5 | 72.9 | 27.9 |
| 285 | 1.24 | 0.13 | 70.8 | 11.3 | 78.4 | 20.3 |
Prothrombin and coagulation factor VII procoagulant activities (FIIc and FVIIc) were expressed as a percentage of normal pooled reference plasma. Plasma acenocoumarol concentrations were measured shortly before intake of the new medication and ranged between 0.03 and 0.09 mg/L. Between K1 and MK-7 treatment there was a 2-week wash-out period.